about
Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?Lack of group X secreted phospholipase A₂ increases survival following pandemic H1N1 influenza infection.Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.Long-term outcome in early survivors of cardiogenic shock at the acute stage of myocardial infarction: a landmark analysis from the French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) Registry.Cyclosporine before PCI in Patients with Acute Myocardial Infarction.In vitro and in vivo models of cerebral ischemia show discrepancy in therapeutic effects of M2 macrophagesNeovascularization derived from cell transplantation in ischemic myocardium.Heart cell implantation after myocardial infarction.Cardiac restoration: frontier or fantasy?Volatile anaesthetics and cardioprotection: lessons from animal studies.Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.Ischaemic postconditioning reduces infarct size: systematic review and meta-analysis of randomized controlled trials.Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials.How to define valvular atrial fibrillation?Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Native Heart Valves.Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation.Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study.Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.Long-Term Outcome and Valve Surgery for Infective Endocarditis in the Systematic Analysis of a Community Study.Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings.Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.Remote ischemic preconditioning in aortic valve surgery: Results of a randomized controlled study.Revisiting myocardial necrosis biomarkers: assessment of the effect of conditioning therapies on infarct size by kinetic modelling.Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project.Opposite and tissue-specific effects of coenzyme Q2 on mPTP opening and ROS production between heart and liver mitochondria: role of complex I.Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction.Preventing acute decrease in renal function induced by coronary angiography (PRECORD): a prospective randomized trial.Cardiac fibroblasts protect cardiomyocytes against lethal ischemia-reperfusion injury.Four-dimensional speckle tracking for assessing improvement in left ventricular contractility after coronary angioplasty.Postconditioning attenuates no-reflow in STEMI patients.[Propionibacterium acnes endocarditis on an aortic prosthesis in a patient carrying a pacemaker].The effect of purinergic signaling via the P2Y11 receptor on vascular function in a rat model of acute inflammation.Effect of cyclosporine on reperfusion injury in acute myocardial infarction.Long-term benefit of postconditioning.Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients.Cyclosporine protects the heart during aortic valve surgery.Relationship of Preexisting Cardiovascular Comorbidities to Newly Diagnosed Atrial Fibrillation After Ischemic Stroke.Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor.Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
P50
Q28275973-6FF9D971-871A-46BE-90BF-C49BE3252FCDQ30361318-0A5D6E02-D90D-48BF-8E0C-26807076D155Q33844478-F1456112-CC2A-454F-A612-E01FC7B66F7CQ34317141-B9856DAA-8FB8-4D58-8F32-72059F99A5B3Q34491582-DCEA153C-2AAD-4CAF-BBAD-0AA9182BF5AAQ34794677-5E035D39-00EA-44FF-A0A7-15D68D6D3BFEQ35949674-79B60139-3B82-463B-89A7-275FB08F8695Q36056519-0603221A-D140-447B-B68C-D5E5E3F9FC23Q36101792-6FCC27FE-D784-4FE5-98FC-793232CD3DFFQ38026951-3E1408F6-5A43-4E4C-A671-8952D6DDDC72Q38233507-A48E4942-F410-4A58-ABB9-563361077C8AQ38277671-0082AA46-634B-44B1-94DD-AB759111613DQ38344695-F7F4AC05-22A4-4EF5-A06D-CC5ABFA3A46BQ38549124-B9C44B6F-70F5-4D69-9E36-72AE90ED440EQ38846506-59F137A5-695C-4315-96C5-B8C7AB9CDC9FQ39322781-F8EAC039-2161-47D9-A181-57C7BEEA36E7Q40556805-F23F389C-C52B-43B0-8D64-B18367267368Q40594118-54CECEC5-BEF9-4227-8DE6-B6D043495D25Q40692673-1A7065CA-3E7F-45D9-8A88-2F4150276D11Q40965917-06158019-00DC-4E18-A5AF-10D34DB3B0EDQ41278761-6A0FC667-9C3D-4640-830B-9D983A294136Q41484978-F79BFDA0-FE37-4592-BB21-F7AE5E6AEFF4Q41632039-B518D29F-003B-4E72-8122-4ED5F032DAF2Q41725911-99DE517E-1CC6-4558-94C9-2CF41274AE38Q42502933-0AA7ED93-7976-492C-A9C6-BD9591062AD2Q43124905-1D1616DA-9BB5-45EF-A058-A91B9AA053C7Q43234427-A9AC246F-4068-4BEF-91FF-D7B73B6D36A0Q45786628-8071C18D-16FE-4A36-8766-8C4DCFF6623DQ45802547-03FC81E1-58A8-491C-9914-9B888FFE5691Q46051532-ECB451E5-BDE5-4DAA-96CE-1AC2686B2E62Q46325809-56ECE734-A42C-4251-8FD1-728A847B533EQ46415953-237A0F79-DABF-4BD1-950B-FAB78D997F00Q46453592-88B86437-4BC6-4514-9676-113F62207B74Q46758924-81038DF9-4304-482C-924C-78DCAC20E7BFQ47378251-DF26736A-AB02-496A-8715-191ED8093B72Q47839377-914C470C-535E-45DA-B25A-5678AAA720D9Q48130046-C3D9BD2A-E344-4E4E-87B8-F39326F71756Q48943611-78098AE4-3396-4B29-9CD7-39AE6CA4E884Q49129555-FC181ECF-3209-4028-9606-F014B09EA4AFQ50934656-A0712A04-0934-4DBD-8467-79F5625C910B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Denis Angoulvant
@ast
Denis Angoulvant
@en
Denis Angoulvant
@es
Denis Angoulvant
@nl
type
label
Denis Angoulvant
@ast
Denis Angoulvant
@en
Denis Angoulvant
@es
Denis Angoulvant
@nl
prefLabel
Denis Angoulvant
@ast
Denis Angoulvant
@en
Denis Angoulvant
@es
Denis Angoulvant
@nl
P106
P108
P1153
8871599800
P31
P496
0000-0003-0788-8092